Cryotherapy technology company Vessi Medical scores $16.5M and more digital health fundings
15 Feb 2024
Preview
Source: mobihealthnews
Photo: gradyreese/Getty Images
Vessi Medical, which offers cryotherapy technology to treat non muscle invasive bladder cancer (NMIBC), announced it closed a $16.5 million Series A funding round.
The Israeli company says its cryotherapy offering is a minimally invasive alternative to transurethral resection of bladder tumor, a surgical first-line therapy in which a surgeon removes the patient's bladder tumor through their urethra.
ALIVE- Israel HealthTech Fund, Agriline and an undisclosed strategic investor led the Series A investment round.
"We are thrilled to announce the closing of this round, especially during this challenging time," Vessi Medical founder and CEO Eyal Kochavi said in a statement.
"The participation of a global strategic investor in this round is a huge show of confidence in Vessi's achievements and potential. The financing led by ALIVE will support expanding Vessi's R&D capabilities, clinical studies in Israel and the U.S. and regulatory clearance, enabling us to achieve our goal of bringing Vessi's treatment for NMIBC to patients and physicians to reduce side effects, improve patient outcomes, and lower health care costs."
Merit Medicine, a company that offers AI technology to companies that self-fund their employees’ health plans, announced it closed a $2 million seed round led by LiveOak Ventures.
Merit utilizes AI to help self-funded employers predict budgeting needs based on datasets on patient journeys, assisting employers in gaining insight into the potential for high-cost medical expenditures and specialty drug utilization for rare, chronic, and complex conditions.
"Self-funded employers are faced with rising healthcare costs and significant financial risk based on the health of their employee base," Mike Marcantonio, who leads the investment for Live Oak Ventures, said in a statement. “Unfortunately, they have very few tools today to evaluate this risk and plan for it."
"When I met the Merit Medicine team, I was inspired by their mission to help employers address this risk by using AI to predict high-cost specialty drug usage and rare, chronic and complex conditions. The team's domain experience also stood out with experience in drug pricing, market access, and healthcare data analytics."
Tags: Vessi Medical, cryotherapy technology, Merit Medicine
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.